0.4734
price down icon3.08%   -0.0166
after-market Handel nachbörslich: .46 -0.0134 -2.83%
loading
Schlusskurs vom Vortag:
$0.49
Offen:
$0.5
24-Stunden-Volumen:
728.44K
Relative Volume:
0.54
Marktkapitalisierung:
$91.34M
Einnahmen:
$8.95M
Nettoeinkommen (Verlust:
$-21.49M
KGV:
-3.945
EPS:
-0.12
Netto-Cashflow:
$-29.24M
1W Leistung:
+18.72%
1M Leistung:
-3.46%
6M Leistung:
-46.03%
1J Leistung:
-58.34%
1-Tages-Spanne:
Value
$0.4601
$0.505
1-Wochen-Bereich:
Value
$0.402
$0.5138
52-Wochen-Spanne:
Value
$0.3651
$1.3999

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name
Firmenname
Lineage Cell Therapeutics Inc
Name
Telefon
510-871-4188
Name
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Name
Mitarbeiter
76
Name
Twitter
@LineageCell
Name
Nächster Verdiensttermin
2025-03-10
Name
Neueste SEC-Einreichungen
Name
LCTX's Discussions on Twitter

Vergleichen Sie LCTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LCTX
Lineage Cell Therapeutics Inc
0.4734 91.34M 8.95M -21.49M -29.24M -0.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.44 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.87 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.49 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.83 24.70B 3.81B -644.79M -669.77M -6.24

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-20 Eingeleitet Craig Hallum Buy
2022-11-02 Eingeleitet Robert W. Baird Outperform
2022-06-14 Eingeleitet B. Riley Securities Buy
2021-08-19 Eingeleitet Noble Capital Markets Outperform
2021-03-31 Eingeleitet Cantor Fitzgerald Overweight

Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten

pulisher
Apr 25, 2025

Lineage Cell Therapeutics Inc [LCTX] Shares Rise 5.57 % on Thursday - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Stem Cell Therapy Market Growth, Trends, & Key Insights | Global - openPR.com

Apr 25, 2025
pulisher
Apr 24, 2025

LCTX’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 24, 2025
pulisher
Apr 22, 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace

Apr 22, 2025
pulisher
Apr 22, 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3 - Business Wire

Apr 22, 2025
pulisher
Apr 22, 2025

-2.44 Fall Turns Lineage Cell Therapeutics Inc (LCTX) Into A Losing Stock For Investors - Marketing Sentinel

Apr 22, 2025
pulisher
Apr 21, 2025

Market Recap: Lineage Cell Therapeutics Inc (LCTX)’s Negative Momentum, Closing at 0.41 - DWinneX

Apr 21, 2025
pulisher
Apr 21, 2025

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) - Business Wire

Apr 21, 2025
pulisher
Apr 21, 2025

Revolutionary Eye Drug Delivery Methods: Lineage CEO Joins Elite Panel at Major Ophthalmology Conference - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga

Apr 17, 2025
pulisher
Apr 09, 2025

BioTime, Inc. : CORRECTION - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

BioTime, Inc. : BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments - marketscreener.com

Apr 09, 2025
pulisher
Apr 08, 2025

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Let’s Dive Into The Lineage Cell Therapeutics Inc (AMEX: LCTX) Stock Forecast. - Marketing Sentinel

Apr 07, 2025
pulisher
Apr 02, 2025

LCTX Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Apr 02, 2025
pulisher
Apr 01, 2025

Weak Fundamental Momentum Sinks Lineage Cell Therapeutics Inc - Marketing Sentinel

Apr 01, 2025
pulisher
Mar 27, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531 - MarketScreener

Mar 27, 2025
pulisher
Mar 25, 2025

Cell Therapy Manufacturing Market Demand, Growth and Future - openPR.com

Mar 25, 2025
pulisher
Mar 21, 2025

It’s Worth A Gamble To Have A Position In Lineage Cell Therapeutics Inc (AMEX: LCTX) At $0.50. - Marketing Sentinel

Mar 21, 2025
pulisher
Mar 18, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Lineage Cell Therapeutics Inc (AMEX: LCTX) Shares Declined By -27.01% In One Month. - Marketing Sentinel

Mar 18, 2025
pulisher
Mar 17, 2025

B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Now Is The Time To Build A Position In Lineage Cell Therapeutics Inc (AMEX:LCTX) - Marketing Sentinel

Mar 13, 2025
pulisher
Mar 13, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Cell Therapy Manufacturing Market Poised for Expansion Biotech - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics stock target cut to $3 by Craig-Hallum - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 11, 2025
pulisher
Mar 10, 2025

Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics earnings beat by $0.01, revenue topped estimates - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - BioSpace

Mar 10, 2025
pulisher
Mar 10, 2025

Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Reports Q4 Revenue Growth, FDA Breakthrough Status for Eye Treatment - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Lineage Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

How Will Lineage Cell Therapeutics Inc (AMEX: LCTX) Look After It Drops -203.77% From Its Highs? - Marketing Sentinel

Mar 07, 2025
pulisher
Mar 05, 2025

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 - BioSpace

Mar 05, 2025

Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
Kapitalisierung:     |  Volumen (24h):